What is BARDA?

Located within the Department of Health and Human Services under the Administration for Strategic Preparedness & Response, BARDA catalyzes the development of medical countermeasures to protect Americans and respond to 21st-century biosecurity threats.

BARDA leverages a variety of private-sector incentives and fuels public-private partnerships that develop critical medical countermeasures for deployment and stockpiling.

Robust funding for BARDA is essential to national and public health security.

BARDA By The Numbers:

- 71 FDA Approvals, Licensures, and Clearances
- 500+ Public Private Partnerships
- 24+ Responses to Emerging Infectious Diseases
- 1320+ TechWatch Market Meetings with Innovative Companies
Collaborative Progress

Through partnerships with industry and academia, BARDA has developed FDA-approved medical countermeasures for threats that range from anthrax to Ebola to burn and wound treatments in the event of a mass casualty.

Protecting our Nation

Due to the lack of funding to address emerging infectious disease threats, BARDA must disrupt or abandon ongoing public-private partnerships when threats emerge. Funding gaps and disruptions squander time and previous investment, reduce the incentive for the private sector to develop needed countermeasures, and leave Americans unprotected from emerging infectious disease outbreaks.

Opportunities for Advocacy

1. Growing the BARDA Budget in Fiscal Year 2024 (FY24). Congress is currently developing our nation’s FY24 budget. You can weigh in!

2. BARDA is authorized under the Pandemic and All-Hazards Preparedness and Advancing Innovation Act. This law expires on September 30, 2023. You can help ensure BARDA is equipped to respond to all future biosecurity threats.

Research!America is requesting $3.7 billion for BARDA for FY24.

REACH OUT TO RESEARCH!AMERICA TO DISCUSS ADVOCACY AIMED AT STRENGTHENING OUR NATION’S BIOSECURITY.

Contact Ashley Arabasadi at aarabasadi@researchamerica.org.